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Abstract: Heather honey was tested for its effect on the formation of biofilms by Staphylococcus aureus,
Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterococcus faecalis, Salmonella Enteriditis
and Acinetobacter baumanii in comparison with Manuka honey. At 0.25 mg/mL, Heather honey inhibited
biofilm formation in S. aureus, A. baumanii, E. coli, S. Enteriditis and P. aeruginosa, but promoted
the growth of E. faecalis and K. pneumoniae biofilms. Manuka honey inhibited biofilm formation in
K. pneumoniae, E. faecalis, and S. Enteriditis, A. baumanii, E. coli and P. aeruginosa, but promoted S. aureus
biofilm formation. Molecular docking with Autodock Vina was performed to calculate the predictive
binding affinities and ligand efficiencies of Manuka and Heather honey constituents for PaDsbA1,
the main enzyme controlling the correct folding of virulence proteins in Pseudomonas aeruginosa.
A number of constituents, including benzoic acid and methylglyoxal, present in Heather and/or
Manuka honey, revealed high ligand efficiencies for the target enzyme. This helps support, to some
extent, the decrease in P. aeruginosa biofilm formation observed for such honeys.
Keywords: antibiofilm; antivirulence; Heather honey; Manuka honey; Pseudomonas aeruginosa
1. Introduction
Antimicrobial drug resistance, particularly in Gram-negative bacteria, is an ever-increasing
challenge for healthcare systems worldwide [1]. Alternative treatment options to conventional
antibiotics are urgently needed to tackle this global threat [2,3]. This includes the discovery of molecules
that could disrupt the ability of pathogens to produce virulence factors [4,5]. In Gram-negative bacteria,
various virulence factors are produced under the control of a master virulence regulatory oxidoreductase
enzyme called DsbA. The latter catalyses the formation of disulfide bonds in proteins and, in doing so,
is instrumental to the process of correct protein folding of bacterial virulence proteins, including type-IV
fimbriae, flagellae and adhesion factors that play a central role in biofilm formation [6–11]. The disulfide
bond forming pathways in Gram-positive bacteria are less well established [12].
Biofilms are formed when microbial communities, held together by a polymeric matrix, attach to
surfaces. The formation of microbial biofilms poses significant risks in healthcare settings when
pathogens attach to wounds, surfaces, and medical devices [13,14]. The opportunistic nosocomial
pathogen, Pseudomonas aeruginosa, is one of the most common bacteria isolated from chronic wounds
Antibiotics 2020, 9, 911; doi:10.3390/antibiotics9120911 www.mdpi.com/journal/antibiotics
Antibiotics 2020, 9, 911 2 of 12
and has become difficult to eradicate due to its ability to form biofilms [15–18]. Its DsbA enzyme is an
attractive target in the search for new antivirulence agents [19,20].
Products from the beehive have a long history of use as traditional remedies [21], and honey
has emerged as a promising topical antibacterial agent [22–26]. Honey is known to contain a
diversity of chemicals which vary depending on nectar sources in different geographical locations,
harvesting seasons, types of bees foraging and storage of the final product [27–29]. The antimicrobial
activity of most honeys has been attributed to a high sugar content, low pH, and the ability to
produce hydrogen peroxide [22,30]. Other contributors to this activity include plant- and bee-derived
chemicals [30]. Both Manuka honey (derived from the nectar of Leptospermum spp.) and Heather honey
(from Erica spp.) have a similar pH, low hydrogen peroxide activity and a high sugar content [31] and
contain various phytochemicals such as phenolic acids and flavonoids [32–35]. Manuka honey is very
rich in methylglyoxal (MGO), a plant-derived compound formed during storage and used for ‘Unique
Manuka Factor’ (UMF) grading [28–30,35,36]. Heather honey, on the other hand, is rich in abscisic
acid [31,37].
Both honeys have demonstrated antibacterial activity [36,38,39] and an inhibitory effect on
polymicrobial biofilms [40]. Manuka honey can disrupt biofilm formation in several pathogens [41–49].
To the best of our knowledge, the effect of Heather honey on monobacterial biofilms has never been
reported, and neither has the potential affinity of Manuka nor Heather honey constituents for DsbA
been predicted. Here, we compared the effect of Heather honey with that of Manuka honey on the
formation of biofilms in seven bacteria. We also employed a molecular docking approach to predict the
binding affinity of constituents from both honeys towards the P. aeruginosa DsbA enzyme (PaDsbA1).
2. Results
2.1. Determination of the Time Required for Optimal Biofilm Formation
Optimal biofilm formation (OD550 nm 0.8–1.7) by all bacterial species was obtained after a 24 h
incubation period. This time point was selected to further study biofilm formation in subsequent
experiments. High amounts of biofilm were also observed after 48 h (OD550 nm 0.7–1.6), less so after
72 and 96 h (Supplementary Materials Figure S1).
2.2. Antibiofilm Activity
At 0.25 mg/mL, Manuka honey showed the strongest inhibition of biofilm formation in
K. pneumoniae, E. faecalis, and S. Enteriditis (92.8, 78.0, and 65.7% inhibition, respectively). It also
inhibited biofilm formation in A. baumanii, E. coli and P. aeruginosa. Unlike Manuka honey, which
increased S. aureus biofilm formation, Heather honey inhibited biofilm formation in S. aureus (69.6%).
It decreased biofilm formation in A. baumanii, E. coli, S. Enteriditis and P. aeruginosa, but promoted the
growth of E. faecalis biofilms (Figure 1). Oleanolic acid decreased biofilm formation in all bacteria
(≥50% in all cases except for E. coli) (Figure 2).
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Figure 1. Inhibition of bacterial biofilm formation by Heather and Manuka honeys (0.25 mg/mL).
Figure 2. Inhibition of biofilm formation by oleanolic acid (OA) tested at a concentration
of 0.0625 mg/mL.
2.3. Molecular Docking of Honey Constituents against P. aeruginosa DsbA1
A guided docking approach was used to predict the binding affinities and ligand efficiency indices
of 56 constituents of Manuka and Heather honey towards PaDsbA1 (Supplementary Materials Table S1).
The best ligand efficiencies were obtained for benzoic acid (0.60), 5-methyl-3-furancarboxylic acid (0.57),
methylglyoxal (0.56) and 5-hydroxymethyl-2-furaldehyde (0.56) (Table 1). The molecular interactions
of each of these ligands with PaDsbA1 are detailed in Table 1 and in Figures 3–6. Benzoic acid strongly
interacted with PaDsbA1 via two hydrogen bonds (contact distances < 2.5 Å) to Tyr148 and Pro20 and
hydrophobic bonds with Leu144, Leu63, Val30, and Val61.
Antibiotics 2020, 9, 911 4 of 12
Table 1. Molecular interactions of Manuka (M)/Heather (H) honey constituents showing the best ligand
efficiencies for PaDsbA1 1.




Residues Distance (Å) Category Type
Benzoic acid (M, H) −5.4 0.60
Tyr148 2.408 H-Bond Conventional
Pro20 1.778 H-Bond Conventional
Leu144 3.456 Hydrophobic Pi-Sigma
Val30 5.365 Hydrophobic Pi-Alkyl
Val61 4.581 Hydrophobic Pi-Alkyl
Leu63 4.592 Hydrophobic Pi-Alkyl
5-methyl-3-furan-
carboxylic acid (M) −5.1 0.57
Tyr148 2.414 H-Bond Conventional
Pro20 1.953 H-Bond Conventional
Val61 4.650 Hydrophobic Alkyl
Leu63 4.838 Hydrophobic Alkyl
Leu144 4.654 Hydrophobic Alkyl
Val61 4.713 Hydrophobic Alkyl
Leu63 4.688 Hydrophobic Alkyl
Methyl-glyoxal (M) −2.8 0.56
Ser22 2.996 H-Bond Conventional
Ser22 3.512 H-Bond CarbonH-Bond
Ser22 3.509 H-Bond CarbonH-Bond
5-hydroxy-methyl-2-
furaldehyde (M) −5.0 0.56
Tyr148 2.343 H-Bond Conventional
Pro20 1.922 H-Bond Conventional
Ser22 3.508 H-Bond CarbonH-Bond
Ser22 3.487 H-Bond CarbonH-Bond
Val30 4.982 Hydrophobic Alkyl
Val61 4.529 Hydrophobic Alkyl
Leu63 4.728 Hydrophobic Alkyl
Leu144 4.541 Hydrophobic Alkyl
1 The control had a docking score of −6.1 kcal/mol and a ligand efficiency of 0.41.
Figure 3. (a) Docked pose of benzoic acid in the PaDsbA1 binding site showing molecular interactions—
hydrogen and hydrophobic bonds shown as green and pink/purple dashed lines, respectively; (b) 2D plot
of interactions between benzoic acid and key residues of PaDsbA1 generated by BIOVIA Discovery
Studio visualizer.
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Figure 4. (a) Docked pose of 5-methyl-3-furancarboxylic acid in the PaDsbA1 binding site showing
molecular interactions—hydrogen and hydrophobic bonds shown as green and pink/purple dashed
lines, respectively; (b) 2D plot of interactions between 5-methyl-3-furancarboxylic acid and key residues
of PaDsbA1 generated by BIOVIA Discovery Studio visualizer.
Figure 5. (a) Docked pose of methylglyoxal in the PaDsbA1 binding site showing molecular
interactions—hydrogen and hydrophobic bonds shown as green and pink/purple dashed lines,
respectively; (b) 2D plot of interactions between methylglyoxal and key residues of PaDsbA1 generated
by BIOVIA Discovery Studio visualizer.
Figure 6. (a) Docked pose of 5-hydroxymethyl-2-furaldehyde in the PaDsbA1 binding site showing
molecular interactions—hydrogen and hydrophobic bonds shown as green and pink/purple dashed
lines, respectively; (b) 2D plot of interactions between 5-hydroxymethyl-2-furaldehyde and key residues
of PaDsbA1 generated by BIOVIA Discovery Studio visualizer.
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3. Discussion
Heather honey has been the subject of a limited number of studies investigating its effect on bacterial
biofilms. Only one study to date has reported its inhibitory activity on mixed Candida–Pseudomonas
biofilms [40]. This prompted us to test its activity against a range of Gram-positive and Gram-negative
single-species biofilms. This was done using a crystal violet assay, a commonly-used indirect method
of biofilm quantification [50], and in comparison with Manuka honey, already known for its ability to
decrease bacterial biofilm formation [41–49]. The decrease in S. aureus, A. baumanii, E. coli, S. Enteriditis
and P. aeruginosa biofilm formation observed for Heather honey is reported here for the first time.
Manuka honey decreased biofilm formation in P. aeruginosa, E. faecalis, A. baumanii, and E. coli,
in agreement with previous studies [45–49]. Its effect on K. pneumoniae and S. Enteriditis biofilms has
not been previously reported. Heather and Manuka honey, both tested at sub-inhibitory concentrations,
increased biofilm formation in the Gram-positive bacteria E. faecalis and S. aureus, respectively. Such an
effect has been observed in other investigations [29,51]. It has been suggested that the decrease in
biofilm formation reported for Manuka honey could be linked to the presence of phenolic compounds,
bee defensin-1 and/or MGO. The latter is able to inhibit biofilm formation by altering the structures of
bacterial fimbriae and flagellae [29,36]. Oleanolic acid is known to decrease biofilm formation [52–55],
but this is the first report of such an effect against E. faecalis, S. aureus, E. coli, K. pneumoniae, A. baumanii
and S. Enteriditis biofilms.
The DsbA enzymes of Gram-negative bacteria have emerged as attractive targets for the discovery
and development of new antivirulence agents including from natural sources [56,57]. There are two
main structural classes of DsbA enzymes, DsbA-I and DsbA-II. Both classes contain proteins that share
highly conserved residues in their catalytic active sites, and also several identical hydrophobic amino
acids adjacent to this site. DsbA-I proteins have a unique groove on their non-catalytic face, opposite to
the active site surface. PaDsbA1 was identified as the main DsbA-I type enzyme in P. aeruginosa [20].
Our molecular docking study was conducted to predict the binding affinity of honey constituents for
the groove on the non-catalytic face the PaDsbA1 [11,20].
Our predictive in silico analysis revealed that benzoic acid, a constituent of both Heather [58] and
Manuka honey [59], could bind with a high efficiency into the pocket of PaDsbA1 where the control
ligand fits [20]. This binding occurs via H-bond interactions between the hydroxyl hydrogen of benzoic
acid and the carbonyl oxygen of Pro20, and between the hydroxyl oxygen of benzoic acid and the
phenolic hydrogen of Tyr148. Interestingly, previous studies reported that benzoic acid could attenuate
the virulence of P. aeruginosa in plants and nematodes through inhibiting the production of virulence
factors such as pyocyanin, and reducing total protease and elastase activity [60]. The latter exoenzyme
plays a critical role in the virulence of P. aeruginosa and requires PaDsbA1 for its biogenesis [6,10,20].
In the case of Manuka honey, our predictions also revealed that MGO had a high binding efficiency for
PaDsbA1. This could support the decrease in P. aeruginosa biofilm formation for this type of honey via
alteration of fimbriae and flagellae. Further work is required to confirm this hypothesis and test MGO
and other honey constituents showing high predictive binding efficiencies in our in silico screening for
their ability to prevent biofilms in wild type bacteria and ∆DsbA mutants.
4. Materials and Methods
4.1. Bacterial Strains, Culture Conditions, and Inoculum Preparation
Staphylococcus aureus (ATCC 43300), Pseudomonas aeruginosa (ATCC 27853), Escherichia coli
(ATCC 25922), Klebsiella pneumoniae (ATCC 700603), Enterococcus faecalis (ATCC 51299) and
Acinetobacter baumanii (ATCC 19606) were obtained from the American Type Culture Collection.
Salmonella enteriditis (NCTC 4444) was obtained from the National Collection of Type Cultures.
In preparation for antibiofilm activity screening, each strain was grown in tryptone soya broth (TSB;
Oxoid, UK) at 37 ◦C for 4 h (late exponential phase) under continuous shaking (250 rpm).
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4.2. Honey Sources and Preparation of Samples
Heather honey was kindly provided by the Scottish Bee Company. Manuka honey (UMF 10+)
was obtained from Wilkin & Sons Ltd., Tiptree, UK. An exactly weighed amount (around 1 g) of each
sample was dissolved in water and then filter-sterilised (0.22 µm disks, Sartorius, UK) to afford stock
solutions of Heather honey and Manuka honey (100 mg/mL).
4.3. Antibiofilm Assay
This was performed according to a previous method with some modifications [61]. Briefly, 100 µL
of each bacterial inoculum (2.5 × 105 CFU/mL) was added to the wells of a 24-flat well polystyrene plate,
containing TSB (1.8 mL). Heather and Manuka honeys were tested at 0.25 mg/mL. Wells containing TSB
only were used as the sterile controls. Oleanolic acid (Sigma-Aldrich, Gillingham, UK), a plant-derived
triterpenoid which inhibits the formation of biofilms in Gram-positive and Gram-negative bacteria,
was used as a positive control [52–55]. Following inoculation, the plates were incubated without
shaking at 37 ◦C for 24, 48, 72, and 96 h to allow the formation of a biofilm at the bottom of the wells as
well as to determine the time point at which the maximum formation of biofilm occurred. After this
period, the supernatants were removed, and the biofilms were washed (×3) with sterile distilled water.
The biofilms were then stained with 1% crystal violet for 5 min, and further washed (×3) with tap
water. A de-staining step was performed using a 7:3 (v/v) mixture of ethanol and acetone and the OD
of the suspension was measured at 550 nm. The percentage of biofilm inhibition was calculated as:
(ODcontrol − ODsample) × 100/ODcontrol.
4.4. Molecular Docking Experiment
4.4.1. Protein Preparation
BIOVIA Discovery Studio Visualizer v.4.5 (Accelrys) was used to remove all water molecules and
hetero-atoms from the three-dimensional crystal structure of the PaDsbA1 protein (PDB ID:5DCH)
which was retrieved, complexed with its ligand inhibitor (MIPS-0000851), from the RCSB Protein Data
Bank (http://www.pdb.org). AutoDock Tools v. 1.5.6rc3 was subsequently used to prepare a PDBQT
file of the target protein containing added polar hydrogen atoms [62].
4.4.2. Ligand Preparation
Flavonoids, phenolic acids, and other miscellaneous compounds previously reported in Manuka
and/or Heather honeys [35,37,58,59,63–74] were selected as ligands for the docking experiment.
All chemical structures were retrieved from SciFinder (https://scifinder.cas.org/scifinder/login).
Each structure was exported to ChemOffice v.16.0 and geometry-optimised using MM2 energy
minimization [75]. The structure of the ligand inhibitor (MIPS-0000851) was obtained from the RCSB
Protein Data Bank (http://www.pdb.org). Docking files for all ligands were prepared using AutoDock
Tools v. 1.5.6rc3 [62]. Rigid docking was performed to minimise standard errors likely due to ligands
with many active rotatable bonds [76]. Gasteiger charges were assigned [77] and the files were saved
as PDBQT formats in preparation for docking.
4.4.3. Grid Box Preparation and Docking Studies
The size of the searching space around the PaDsbA1 binding site residues was defined with grid
box parameters prepared using AutoDock Tools v. 1.5.6rc3, and the molecular docking was done with
AutoDock Vina v. 1.1.2 [76]. The centre of the grid box was set to x = 21.7657, y = 35.6275, z = −2.0723.
Its size was 22 × 22 × 22 points in the x, y, z dimensions. The spacing was set at 1 Å. MIPS-0000851,
a known PaDsbA1 inhibitor, was retrieved from its co-crystallised complex with the target protein and
re-docked as a control against the enzyme to validate the docking conditions. Different orientations
of the ligands were searched and ranked based on their energy scores. Upon visual inspection of
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all binding poses obtained, only poses with the lowest root mean square deviation (RMSD) value
(threshold < 1.00 Å) were considered to provide a high accuracy of docking. The default values set
in Autodock Vina were used as the parameters for the rigid-ligand docking (exhaustiveness = 8).
The docking scores were calculated as the predicted free energies of binding (∆G in kcal/mol).
Ligand efficiencies were calculated as the ratio of ∆G to the number of heavy atoms (NHA) for each
ligand (LE = –(∆G)/NHA) [78] (Table 1 and Table S1).
4.4.4. Protein-Ligand Interactions and Predictive Inhibition
BIOVIA Discovery Studio Visualizer v.4.5 (Accelrys) was used to identify the H-bonds and
non-bonding interactions between the ligand docking poses and the binding site of PaDsbA1 (Table 1
and Supplementary Materials Table S1).
5. Conclusions
We have shown that benzoic acid (in Manuka and Heather honey) and other small molecules
including MGO (in Manuka honey) have the potential to target virulence in P. aeruginosa.
Further investigations should aim to analyse the effect of Heather honey on P. aeruginosa biofilm
morphology using confocal laser scanning microscopy and identify the nature of its active constituent(s).
Additional molecular docking could be performed to establish whether binding of honey constituents
occurs in other DsbA enzymes that share a similarity with PaDsbA1 (e.g., Acinetobacter baumannii
AbDsbA). As Manuka and Heather honeys display bactericidal activity against P. aeruginosa [79],
they represent an interesting alternative/complementary option to treat persistent wounds infected
with this pathogen.
Supplementary Materials: The following are available online at http://www.mdpi.com/2079-6382/9/12/911/s1,
Figure S1: Time course assay for the determination of the optimal bacterial biofilm formation time, Table S1:
Docking scores and ligand efficiencies of Manuka and/or Heather honey constituents towards PaDsbA1.
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9. Bocian-Ostrzycka, K.M.; Grzeszczuk, M.J.; Banaś, A.M.; Jagusztyn-Krynicka, E.K. Bacterial thiol
oxidoreductases—From basic research to new antibacterial strategies. Appl. Microbiol. Biotechnol. 2017,
101, 3977–3989. [CrossRef]
10. Lasica, A.M.; Jagusztyn-Krynicka, E.K. The role of Dsb proteins of Gram-negative bacteria in the process of
pathogenesis. FEMS Microbiol. Rev. 2007, 31, 626–636. [CrossRef]
11. Totsika, M.; Vagenas, D.; Paxman, J.J.; Wang, G.; Dhouib, R.; Sharma, P.; Martin, J.L.; Scanlon, M.J.; Heras, B.
Inhibition of Diverse DsbA Enzymes in Multi-DsbA Encoding Pathogens. Antioxid. Redox Signal. 2018,
29, 653–666. [CrossRef] [PubMed]
12. Reardon-Robinson, M.E.; Ton-That, H. Disulfide-Bond-Forming Pathways in Gram-Positive Bacteria.
J. Bacteriol. 2015, 198, 746–754. [CrossRef]
13. Kumar, A.; Alam, A.; Rani, M.; Ehtesham, N.Z.; Hasnain, S.E. Biofilms: Survival and defense strategy for
pathogens. Int. J. Med. Microbiol. 2017, 307, 481–489. [CrossRef]
14. Muhammad, M.H.; Idris, A.L.; Fan, X.; Guo, Y.; Yu, Y.; Jin, X.; Qiu, J.; Guan, X.; Huang, T. Beyond Risk:
Bacterial Biofilms and Their Regulating Approaches. Front. Microbiol. 2020, 11, 928. [CrossRef]
15. Lee, K.; Yoon, S.S. Pseudomonas aeruginosa Biofilm, a Programmed Bacterial Life for Fitness.
J. Microbiol. Biotechnol. 2017, 27, 1053–1064. [CrossRef] [PubMed]
16. Pang, Z.; Raudonis, R.; Glick, B.R.; Lin, T.-J.; Cheng, Z. Antibiotic resistance in Pseudomonas aeruginosa:
Mechanisms and alternative therapeutic strategies. Biotechnol. Adv. 2019, 37, 177–192. [CrossRef] [PubMed]
17. Clinton, A.; Carter, T. Chronic Wound Biofilms: Pathogenesis and Potential Therapies. Lab. Med. 2015,
46, 277–284. [CrossRef] [PubMed]
18. Serra, R.; Grande, R.; Butrico, L.; Rossi, A.; Settimio, U.F.; Caroleo, B.; Amato, B.; Gallelli, L.; De Franciscis, S.
Chronic wound infections: The role of Pseudomonas aeruginosa and Staphylococcus aureus. Expert Rev.
Anti-Infect. Ther. 2015, 13, 605–613. [CrossRef]
19. Ha, U.-H.; Wang, Y.; Jin, S. DsbA of Pseudomonas aeruginosa Is Essential for Multiple Virulence Factors.
Infect. Immun. 2003, 71, 1590–1595. [CrossRef]
20. Mohanty, B.; Rimmer, K.; McMahon, R.M.; Headey, S.J.; Vazirani, M.; Shouldice, S.R.; Coinçon, M.; Tay, S.;
Morton, C.J.; Simpson, J.S.; et al. Fragment library screening identifies hits that bind to the non-catalytic
surface of Pseudomonas aeruginosa DsbA1. PLoS ONE 2017, 12, e0173436. [CrossRef]
21. Viuda-Martos, M.; Ruiz-Navajas, Y.; Fernández-López, J.; Pérez-Álvarez, J. Functional Properties of Honey,
Propolis, and Royal Jelly. J. Food Sci. 2008, 73, R117–R124. [CrossRef] [PubMed]
22. Mandal, M.D.; Mandal, S. Honey: Its medicinal property and antibacterial activity. Asian Pac. J. Trop. Biomed.
2011, 1, 154–160. [CrossRef]
23. Hussain, M.B. Role of Honey in Topical and Systemic Bacterial Infections. J. Altern. Complement. Med. 2018,
24, 15–24. [CrossRef]
24. Temaru, E.; Shimura, S.; Amano, K.; Karasawa, T. Antibacterial activity of honey from stingless honeybees
(Hymenoptera; Apidae; Meliponinae). Pol. J. Microbiol. 2007, 56, 281–285. [PubMed]
25. Maddocks, S.E.; Jenkins, R.E. Honey: A sweet solution to the growing problem of antimicrobial resistance?
Future Microbiol. 2013, 8, 1419–1429. [CrossRef]
26. Minden-Birkenmaier, B.A.; Bowlin, G.L. Honey-Based Templates in Wound Healing and Tissue Engineering.
Bioengineering 2018, 5, 46. [CrossRef]
27. Da Silva, P.M.; Gauche, C.; Gonzaga, L.V.; Costa, A.C.O.; Fett, R. Honey: Chemical composition, stability and
authenticity. Food Chem. 2016, 196, 309–323. [CrossRef]
28. Albaridi, N.A. Antibacterial Potency of Honey. Int. J. Microbiol. 2019, 2019, 1–10. [CrossRef]
29. Nolan, V.C.; Harrison, J.; Cox, J. Dissecting the Antimicrobial Composition of Honey. Antibiotics 2019, 8, 251.
[CrossRef]
30. Kwakman, P.H.S.; Zaat, S.A.J. Antibacterial components of honey. IUBMB Life 2012, 64, 48–55. [CrossRef]
31. Fyfe, L.; Okoro, P.; Paterson, E.; Coyle, S.; McDougall, G.J. Compositional analysis of Scottish honeys with
antimicrobial activity against antibiotic-resistant bacteria reveals novel antimicrobial components. LWT Food
Sci. Technol. 2017, 79, 52–59. [CrossRef]
Antibiotics 2020, 9, 911 10 of 12
32. Dezmirean, G.I.; Mărghitaş, L.A.; Bobiş, O.; Dezmirean, D.S.; Bonta, V.; Erler, S. Botanical Origin Causes
Changes in Nutritional Profile and Antioxidant Activity of Fermented Products Obtained from Honey.
J. Agric. Food Chem. 2012, 60, 8028–8035. [CrossRef] [PubMed]
33. Karabagias, I.K.; Maia, M.; Karabagias, V.K.; Gatzias, I.; Badeka, A.V. Characterization of Eucalyptus,
Chestnut and Heather Honeys from Portugal Using Multi-Parameter Analysis and Chemo-Calculus. Foods
2018, 7, 194. [CrossRef] [PubMed]
34. Kavanagh, S.; Gunnoo, J.; Passos, T.M.; Stout, J.C.; White, B. Physicochemical properties and phenolic content
of honey from different floral origins and from rural versus urban landscapes. Food Chem. 2019, 272, 66–75.
[CrossRef]
35. Mavric, E.; Wittmann, S.; Barth, G.; Henle, T. Identification and quantification of methylglyoxal as the
dominant antibacterial constituent of Manuka (Leptospermum scoparium) honeys from New Zealand. Mol. Nutr.
Food Res. 2008, 52, 483–489. [CrossRef]
36. Johnston, M.; McBride, M.; Dahiya, D.; Owusu-Apenten, R.; Nigam, P.S. Antibacterial activity of Manuka
honey and its components: An overview. AIMS Microbiol. 2018, 4, 655–664. [CrossRef]
37. Ferreres, F.; Andrade, P.; Tomás-Barberán, F.A. Natural Occurrence of Abscisic Acid in Heather Honey and
Floral Nectar. J. Agric. Food Chem. 1996, 44, 2053–2056. [CrossRef]
38. Salonen, A.; Virjamo, V.; Tammela, P.; Fauch, L.; Julkunen-Tiitto, R. Screening bioactivity and bioactive
constituents of Nordic unifloral honeys. Food Chem. 2017, 237, 214–224. [CrossRef]
39. Feás, X.; Iglesias, A.; Rodrigues, S.; Estevinho, L.M. Effect of Erica sp. Honey against Microorganisms of
Clinical Importance: Study of the Factors Underlying this Biological Activity. Molecules 2013, 18, 4233–4246.
[CrossRef]
40. Fernandes, L.; Oliveira, A.; Henriques, M.; Rodrigues, M.E. Honey as a Strategy to Fight Candida tropicalis
in Mixed-Biofilms with Pseudomonas aeruginosa. Antibiotics 2020, 9, 43. [CrossRef]
41. Lu, J.; Turnbull, L.; Burke, C.M.; Liu, M.; Carter, D.A.; Schlothauer, R.C.; Whitchurch, C.B.; Harry, E.J.
Manuka-type honeys can eradicate biofilms produced by Staphylococcus aureusstrains with different
biofilm-forming abilities. PeerJ 2014, 2, e326. [CrossRef] [PubMed]
42. Paramasivan, S.; Drilling, A.; Jardeleza, C.; Jervis-Bardy, J.; Vreugde, S.; Wormald, P.J.
Methylglyoxal-augmented Manuka honey as a topical anti-Staphylococcus aureus biofilm agent: Safety and
efficacy in an in vivo model. Int. Forum Allergy Rhinol. 2014, 4, 187–195. [CrossRef]
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